


**Trial Description:** Patients with clinically confirmed Marfan syndrome were randomized to irbesartan 300 mg daily vs. placebo.



## RESULTS

- Primary efficacy endpoint, mean rate of aortic root dilatation, was 0.53 mm per year in the irbesartan group vs. 0.74 mm per year in the placebo group ( $p = 0.030$ )
- Difference in systolic blood pressure at 1 year (irbesartan vs. placebo): -6.3 mm Hg
- Serious adverse events: 24% with irbesartan vs. 23% with placebo

## CONCLUSIONS

- Among patients with Marfan syndrome, irbesartan was associated with a reduction in the rate of aortic root dilatation compared with placebo
- Although further investigation is needed, this study supports the use of irbesartan to slow the rate of aortic root dilatation in patients with Marfan syndrome

Mullen M, et al. Lancet 2019;394:2263-70